Exchange: NASDAQ·Updated 06:19 PM EDT
News
all
press releases
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
Zacks
More News
Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?
Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.
Zacks
EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus
Editas beats Q2 estimates as collaboration revenues surge, while EDIT-401 advanced toward clinical testing with encouraging preclinical data.
Zacks
Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of +50.00% and +524.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Geron (GERN) Reports Q2 Loss, Beats Revenue Estimates
Geron (GERN) delivered earnings and revenue surprises of -100.00% and +4.49%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026...
Yahoo! Finance: News
Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday
Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries, Qfin Holdings, Editas Medicine, and others.read more...
Benzinga
EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus
Editas narrows Q1 loss as costs fall, but revenues drop sharply. Pipeline focus shifts to in vivo gene editing and lead candidate EDIT-401.
Zacks
Company News for May 6, 2026
Companies in The News Are: MPC,EDIT,BUD,AEP
Zacks

Advertisement|Remove ads.